patentstorm.us 258 85 http://www.patentstorm.us/ http://www.patentstorm.us/images/logo.gif PatentStorm -> Applications -> Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof http://www.patentstorm.us/rss/class/applications/rss-530.xml Recent patent applications filings in USPTO Class 530 Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof. Thu, 16 Feb 2012 15:00:11 patents@patentstorm.us en <![CDATA[Antibody fusion-mediated plant resistance against Oomycota]]> http://www.patentstorm.us/applications/20120042416/description.html
  • Application Number:  20120042416
  • Publication Date:  2012-02-16
  • Inventors:  Fischer, Rainer; Schillberg, Stefan; Schleker, Sylvia; Peschen, Dieter
    • The present invention relates to fusion proteins comprising anti-Oomycotic proteins or peptides linked to an antibody or fragment thereof specifically recognising an epitope of an Oomycota. The invention is also directed to polynucleotides coding for the fusion proteins. The embodiments of the present invention are particularly useful for the protection of plants against Oomycota. The invention therefore comprises transgenic plants expressing the fusion proteins of the present ...
    ]]>     20120042416     <![CDATA[Methods And Compositions For Targeting Sequences Of Interest To The Chloroplast]]> http://www.patentstorm.us/applications/20120042412/description.html
  • Application Number:  20120042412
  • Publication Date:  2012-02-16
  • Inventors:  Siehl, Daniel L.; Castle, Linda A.; Albert, Henrik; Heckert, Matthew; Lu, Jian; Tao, Yumin
    • Chimeric polynucleotides comprising a nucleotide sequence encoding a chloroplast transit peptide operably linked to a heterologous polynucleotide of interest are provided, wherein the chloroplast transit peptide comprises an amino acid sequence having the chloroplast transit peptide sequence as set forth in SEQ ID NO:1 or a biologically active variant or fragment thereof or wherein the chloroplast transit peptide comprises the sequence set forth in SEQ ID NO: 58 or an active variant or fragment ...
    ]]>     20120042412     <![CDATA[ABSCISIC ACID CARRIER GENE AND TRANSGENIC PLANT EXPRESSING THE SAME]]> http://www.patentstorm.us/applications/20120042410/description.html
  • Application Number:  20120042410
  • Publication Date:  2012-02-16
  • Inventors:  Lee, Young-Sook; Lee, Mi-Young; Martionia, Enrico; Kang, Joo-Hyun
    • The present invention relates to carrier genes of abscisic acid and the transgenic plant prepared using such genes, and more specifically to genes that enhance resistance to salt or dryness in relation to abscisic acid transport and the recombinant vectors including the genes, the transgenic plant prepared using the recombinant vector, a transgenic plant that is superior in terms of resistance to base and dryness, a method for environmental purification in arid regions based on the plants, and ...
    ]]>     20120042410     <![CDATA[RTD RECEPTOR]]> http://www.patentstorm.us/applications/20120042400/description.html
  • Application Number:  20120042400
  • Publication Date:  2012-02-16
  • Inventors:  Gurney, Austin; Ashkenazi, Avi J.
    • Novel polypeptides, designated RTD, which are capable of binding Apo-2 ligand are provided. Compositions including RTD chimeras, nucleic acid encoding RTD, and antibodies to RTD are also ...
    ]]>     20120042400     <![CDATA[IMMUNOGENIC PEPTIDES]]> http://www.patentstorm.us/applications/20120042399/description.html
  • Application Number:  20120042399
  • Publication Date:  2012-02-16
  • Inventors:  Banham, Alison; Pulford, Karen; Anderson, Amanda; Ait-Taho-ar, Kamel
    • The present invention relates to immunogenic peptides and their various applications. In particular the invention relates to immunogenic peptides derived from the PASD1 protein and their use in therapeutic, diagnostic and prognostic ...
    ]]>     20120042399     <![CDATA[PHAGE ANTIBODIES TO RADIATION-INDUCIBLE NEOANTIGENS]]> http://www.patentstorm.us/applications/20120041303/description.html
  • Application Number:  20120041303
  • Publication Date:  2012-02-16
  • Inventors:  Hallahan, Dennis E.; Mernaugh, Raymond
    • A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. The method includes the steps of: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are therapeutic and diagnostic methods using targeting ligands that bind ...
    ]]>     20120041303     <![CDATA[CELLULOSE MATERIALS WITH NOVEL PROPERTIES]]> http://www.patentstorm.us/applications/20120041183/description.html
  • Application Number:  20120041183
  • Publication Date:  2012-02-16
  • Inventors:  Hu, Thomas Q.; Hayek, Ali
    • A molecule possessing a primary or secondary amino group and an additional functionality capable of providing a novel or improved property to a cellulose material has been permanently attached to the cellulose material in aqueous media using a water-soluble carbodiimide as the coupling agent/activator. One such molecule is 5-aminofluorescein (abbreviated as “A-fluo”) and one such cellulose material is a papermaking pulp. Papers made from a pulp furnish containing, for example, 0.01 wt. % of ...
    ]]>     20120041183     <![CDATA[Water Soluble Cholesterol Derivatives]]> http://www.patentstorm.us/applications/20120041182/description.html
  • Application Number:  20120041182
  • Publication Date:  2012-02-16
  • Inventors:  Travis, Benjamin R.; Huang, Lijun M.
    • Four novel water soluble cholesterol derivative compounds are disclosed. These compounds have various applications in studies of membrane proteins, including drug screening and studies of receptor stability and folding. In one aspect the water soluble cholesterol derivatives disclosed may be used to replace cholesterol in micelle-solubilized membrane protein ...
    ]]>     20120041182     <![CDATA[FUSION PROTEINS FORMING TRIMERS]]> http://www.patentstorm.us/applications/20120041181/description.html
  • Application Number:  20120041181
  • Publication Date:  2012-02-16
  • Inventors:  Hill, Oliver; Gieffers, Christian; Thiemann, Meinolf; Branschaedel, Marcus
    • The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described ...
    ]]>     20120041181     <![CDATA[Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses]]> http://www.patentstorm.us/applications/20120041180/description.html
  • Application Number:  20120041180
  • Publication Date:  2012-02-16
  • Inventors:  SHEFFER, Joseph; NORMAN, Thea; CHO, Ho Sung; TIAN, Feng; HAYS PUTNAM, Anna-Maria A.; DIMARCHI, Richard D.; CHU, Stephanie; KRAWITZ, Denise
    • Modified human plasma polypeptides or Fc and uses thereof are ...
    ]]>     20120041180     <![CDATA[Preparation and Purification of Subunit Vaccine for Neisseria Meningitidis (NM) Group B Isolates]]> http://www.patentstorm.us/applications/20120041179/description.html
  • Application Number:  20120041179
  • Publication Date:  2012-02-16
  • Inventors:  Leng, Chih-Hsiang; Chong, Pele Choi-Sing; Hsieh, Shih-Yang; Lin, Chang-Ling
    • A method for preparing and purifying recombinant lipoprotein Ag473 of Neisseria meningitidis (NM) group B isolates. The method can be used in large-scale production of vaccines for Neisseria meningitidis (NM) group ...
    ]]>     20120041179     <![CDATA[Coenzyme Q10 Nanoparticles, Preparation Method Thereof and Composition Containing Said Nanoparticles]]> http://www.patentstorm.us/applications/20120041178/description.html
  • Application Number:  20120041178
  • Publication Date:  2012-02-16
  • Inventors:  Chung, Bong Hyun; Han, Jung Hyun
    • Provided are a coenzyme Q10 nanoparticle, a method of preparing the same and a composition having the nanoparticle. According to the present invention, Coenzyme Q10 may be dissolved in only a water-miscible organic solvent, and easily made into a nano-sized particle and solubilized under a low energy condition, for example, by simple stirring. The coenzyme Q10 may be dispersion-stabilized by an amino acid or protein. The coenzyme Q10 is formed in a nano-sized particle and solubilized, an ...
    ]]>     20120041178     <![CDATA[METHOD OF PRODUCING POLYMERS OF SPIDER SILK PROTEINS]]> http://www.patentstorm.us/applications/20120041177/description.html
  • Application Number:  20120041177
  • Publication Date:  2012-02-16
  • Inventors:  Johansson, Jan; Rising, Anna; Hedhammar, My; Nordling, Kerstin
    • A method of producing polymers of an isolated spider silk protein involves providing a solution of said spider silk protein in a liquid medium at pH 6.4 or higher and/or an ion composition that prevents polymerisation of the spider silk protein. The properties of the liquid medium are adjusted to a pH of 6.3 or lower and an ion composition that allows polymerisation of the spider silk protein. The spider silk protein is allowed to form polymers in the liquid medium, and the resulting spider ...
    ]]>     20120041177     <![CDATA[UCP4]]> http://www.patentstorm.us/applications/20120041176/description.html
  • Application Number:  20120041176
  • Publication Date:  2012-02-16
  • Inventors:  Pan, James; Zhong, Alan; Adams, Sean
    • The present invention is directed to novel polypeptides having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the ...
    ]]>     20120041176     <![CDATA[NOVEL AUTOGRAPHY REGULATORS ATG14L AND RUBICON]]> http://www.patentstorm.us/applications/20120041175/description.html
  • Application Number:  20120041175
  • Publication Date:  2012-02-16
  • Inventor:  Yue, Zhenyu
    • The present invention provides for up- and down-regulation of cellular autophagy, e.g., for treating cancer or neurological disease. The invention results, in part, from discovery of two novel proteins, ATG14L (previously called “BISC”) and Rubicon (previously called “BIRC”), which bind to a Class III phophatidylinositol 3′-kinase (PI3K)/Vps34-Beclin 1 autophagic complex. ATG14L and Rubicon each regulate autophagic activity in an opposing manner. ATG14L and Rubicon can be used, for ...
    ]]>     20120041175     <![CDATA[Counter Current Purification of Polypeptides]]> http://www.patentstorm.us/applications/20120041174/description.html
  • Application Number:  20120041174
  • Publication Date:  2012-02-16
  • Inventor:  Frederiksen, Søren Søndergaard
    • The present invention relates to methods for the purification of polypeptides using counter current chromatography. In particular the present invention relates to the use of counter current chromatography for the purification of recombinant ...
    ]]>     20120041174     <![CDATA[WATER SOLUBLE SOLID PHASE PEPTIDE SYNTHESIS]]> http://www.patentstorm.us/applications/20120041173/description.html
  • Application Number:  20120041173
  • Publication Date:  2012-02-16
  • Inventor:  Collins, Jonathan M.
    • A solid phase peptide synthesis method is disclosed. The method includes the steps of deprotecting an amino group in its protected form that is protected with a protecting group containing a Michael acceptor site composed of an α,β-unsaturated sulfone in a solvent selected from the group consisting of water, alcohol, and mixtures of water and alcohol; washing the deprotected acid in a solvent selected from the group consisting of water, alcohol, and mixtures of water and alcohol; coupling the ...
    ]]>     20120041173     <![CDATA[METHOD FOR THE MANUFACTURE OF DEGARELIX]]> http://www.patentstorm.us/applications/20120041172/description.html
  • Application Number:  20120041172
  • Publication Date:  2012-02-16
  • Inventors:  Zhang, Haixiang; Fomsgaard, Jens; Staerkaer, Gunnar
    • In a step-wise synthesis of degarelix comprising 0.3% by weight or less of 4-([2(5-hydantoyl)]acetylamino)-phenylalanine analog on (solid support)-NH2 a step comprises providing a solution of an amino acid or peptide of which the α-amino group is protected by Fmoc; contacting the support with the solution in the presence of reagent for forming a peptide bond between a carboxyl group of the amino acid or peptide and (solid support)-NH2; removing Fmoc by contacting the ...
    ]]>     20120041172     <![CDATA[PROCESS FOR THE PRODUCTION OF A RECOMBINANT POLYPEPTIDE OF INTEREST]]> http://www.patentstorm.us/applications/20120041171/description.html
  • Application Number:  20120041171
  • Publication Date:  2012-02-16
  • Inventors:  Stam, Hein; Roubos, Johannes Andries; Van Peij, Noel Nicolaas Maria Elisabeth; Van De Vondervoort, Peter Jozef Ida
    • The present invention relates to a process for the production of a recombinant polypeptide of interest, a polypeptide obtained by said process, a recombinant polynucleotide, an expression vector, an expression construct and to the use of a specific signal peptide and of a polynucleotide encoding said specific signal peptide for the production of a recombinant polypeptide of ...
    ]]>     20120041171     <![CDATA[PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID]]> http://www.patentstorm.us/applications/20120040918/description.html
  • Application Number:  20120040918
  • Publication Date:  2012-02-16
  • Inventors:  Park, Hyun-Jin; Lee, Jong-Ook; Chung, Shin; Kim, Heui-Yeon; Kim, Mi-Ran
    • The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic ...
    ]]>     20120040918     <![CDATA[Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease]]> http://www.patentstorm.us/applications/20120040917/description.html
  • Application Number:  20120040917
  • Publication Date:  2012-02-16
  • Inventors:  SAZANI, PETER L.; ØRUM, HENRIK
    • The present invention relates to compositions and methods for preparing splice variants of TNFalpha receptor (TNFR) in vivo or in vitro, and the resulting TNFR protein variants. Such variants may be prepared by controlling the splicing of pre-mRNA molecules and regulating protein expression with splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 or 8 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically ...
    ]]>     20120040917     <![CDATA[PEPTIDES AND NANOPARTICLES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS]]> http://www.patentstorm.us/applications/20120040915/description.html
  • Application Number:  20120040915
  • Publication Date:  2012-02-16
  • Inventors:  Mukhopadhyay, Debabrata; Mukherjee, Priyabrata; Spaller, Mark
    • Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as ...
    ]]>     20120040915     <![CDATA[PROTEASOME-ACTIVATING ANTI-AGING PEPTIDES AND COMPOSITIONS CONTAINING SAME]]> http://www.patentstorm.us/applications/20120040912/description.html
  • Application Number:  20120040912
  • Publication Date:  2012-02-16
  • Inventors:  Domloge, Nouha; Dal Farra, Claude; Botto, Jean-Marie
    • The present invention relates to peptidic compounds of general formula (I):


    R1—X1—X2-Asp-Cys-Arg-X3—X4-(AA)p-R2.

    In addition, the present invention relates to, on the one hand, a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a cosmetically or pharmaceutically ...
    ]]> 20120040912 <![CDATA[IDENTIFICATION OF NOVEL ANTAGONIST TOXINS OF T-TYPE CALCIUM CHANNEL FOR ANALGESIC PURPOSES]]> http://www.patentstorm.us/applications/20120040909/description.html

  • Application Number:  20120040909
  • Publication Date:  2012-02-16
  • Inventors:  Escoubas, Pierre; Bourinet, Emmanuel; Marger, Fabrice; Nargeot, Joel; Lazdunski, Michel
    • A peptide with the following sequence YCQKFLWTCDSERPCCEGLVCRLWCKIN (SEQ ID NO 1) or a derivative thereof, and nucleic acids coding for the peptide having the sequence (SEQ ID NO 1). Also the use of this peptide as an antagonist and/or reverse agonist of T-type calcium channels. A use of the peptide for preparing a drug, in particular an analgesic ...
    ]]>     20120040909     <![CDATA[PROTEIN TARGETS IN DISEASE]]> http://www.patentstorm.us/applications/20120040906/description.html
  • Application Number:  20120040906
  • Publication Date:  2012-02-16
  • Inventors:  Samali, Afshin; Gupta, Sanjeev
    • MicroRNAs have been shown to be critically involved in control of cell survival and cell death decisions. By identifying microRNAs implicated in Endoplasmic Reticulum stress-induced cardiomyocyte apoptosis, it is envisaged that protein targets involved in same can be identified through specifically selected microRNAs. The microRNAs targeted are miR-351, miR-322, miR-125, miR-424 and miR-7a. Furthermore, the potential application of these identified proteins in the treatment of cardiovascular ...
    ]]>     20120040906     <![CDATA[MEANS FOR PURIFYING A COAGULATION PROTEIN, AND METHODS FOR IMPLEMENTING SAME]]> http://www.patentstorm.us/applications/20120040905/description.html
  • Application Number:  20120040905
  • Publication Date:  2012-02-16
  • Inventors:  Nogre, Michel; Perret, Gerald
    • An affinity substrate for selectively binding a coagulation protein, includes a substrate solid on which nucleic aptamers binding specifically to the coagulation protein are ...
    ]]>     20120040905     <![CDATA[COMPOSITIONS OF AND METHODS OF USING LIGAND DIMERS]]> http://www.patentstorm.us/applications/20120040900/description.html
  • Application Number:  20120040900
  • Publication Date:  2012-02-16
  • Inventors:  Griffith, Linda G.; Lee, Richard T.; Alvarez, Luis M.
    • Provided herein are ligand dimers, compositions thereof, as well as methods of their use. The ligand dimers provided can comprise at least one ligand to a Her receptor and can be used to force dimerization of specific receptor pairs. The forced dimerization of specific receptor pairs can be used to control (e.g., promote or inhibit) signaling, and, therefore, the ligand dimers provided can also be used in various forms of treatment in which such signaling control is beneficial to a subject. It ...
    ]]>     20120040900     <![CDATA[COMPOSITIONS, METHODS AND USES FOR MODULATION OF BRCA 1]]> http://www.patentstorm.us/applications/20120040896/description.html
  • Application Number:  20120040896
  • Publication Date:  2012-02-16
  • Inventors:  Holt, Jeffrey Thomas; Anderson, Steve; Nelson, Andrew Cook
    • Embodiments of the present invention generally relate to methods, compositions and uses for diagnosis and treatment of cancer. Certain embodiments report methods and compositions for diagnosing and/or treating a subject having a BRCA1-related cancer or sporadic cancer. Some embodiments disclose treatments that can include, but are not limited to, modulation of BRCA1. In some embodiments, methods for identifying a subject with unstable BRCA1 protein are ...
    ]]>     20120040896     <![CDATA[Mini-Hepcidin Peptides and Methods of Using thereof]]> http://www.patentstorm.us/applications/20120040894/description.html
  • Application Number:  20120040894
  • Publication Date:  2012-02-16
  • Inventors:  Nemeth, Elizabeta; Ganz, Tomas; Preza, Gloria; Ruchala, Piotr
    • Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using ...
    ]]>     20120040894     <![CDATA[Methods and Compositions for the Treatment of Heart Failure and Other Disorders]]> http://www.patentstorm.us/applications/20120040892/description.html
  • Application Number:  20120040892
  • Publication Date:  2012-02-16
  • Inventors:  Currie, Mark; Milne, G. Todd; Zimmer, Daniel; Fretzen, Angelika
    • Peptides that act as GC-C receptor agonists and contain at least one D-cys and are useful for the treatment of diuresis and heart disease as well as other disorders are ...
    ]]>     20120040892     <![CDATA[HIV FUSION INHIBITOR PEPTIDES WITH IMPROVED BIOLOGICAL PROPERTIES]]> http://www.patentstorm.us/applications/20120040891/description.html
  • Application Number:  20120040891
  • Publication Date:  2012-02-16
  • Inventors:  Dwyer, John J.; Johnston, Barbara E.; Bray, Brian L.; Friedrich, Paul E.; Tvermoes, Nicolai A.; Zhang, Huyi; Schneider, Stephen E.
    • Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these ...
    ]]>     20120040891     <![CDATA[PEPTIDOMIMETIC MACROCYCLES]]> http://www.patentstorm.us/applications/20120040889/description.html
  • Application Number:  20120040889
  • Publication Date:  2012-02-16
  • Inventors:  Annis, David Allen; Nash, Huw M.
    • The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of viral ...
    ]]>     20120040889     <![CDATA[Analogues of Neuropeptide Y Having Proline Substitution At Position 34]]> http://www.patentstorm.us/applications/20120040886/description.html
  • Application Number:  20120040886
  • Publication Date:  2012-02-16
  • Inventor:  Dong, Zheng Xin
    • The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having proline substitution at position 34 and other substitution(s) as defined herein that selectively bind to the neuropeptide Y1 receptor subtype ...
    ]]>     20120040886     <![CDATA[Analogues of Neuropeptide Y Having At Least One Synthetic Amino Acid Substitution]]> http://www.patentstorm.us/applications/20120040885/description.html
  • Application Number:  20120040885
  • Publication Date:  2012-02-16
  • Inventors:  Deoliveira, Daniel B.; Zhou, Kevin; Dong, Zheng Xin
    • The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having at least one unnatural amino acid substitution, such as 4Hyp at position 34, that selectively bind to the neuropeptide Y1 receptor subtype compared ...
    ]]>     20120040885     <![CDATA[Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration]]> http://www.patentstorm.us/applications/20120040884/description.html
  • Application Number:  20120040884
  • Publication Date:  2012-02-16
  • Inventor:  Hageman, Gregory S.
    • Disclosed are screening methods for determining a human subject's propensity to develop a vascular disorder and/or age-related macular degeneration (AMD), therapeutic or prophylactic compounds for treating disease or inhibiting its development, and methods of treating patients to alleviate symptoms of the disease, prevent or delay its onset, or inhibit its progression. The inventions are based on the discovery that persons with a genome having a deletion of the CFHR-1 and/or CFHR-3 gene, which ...
    ]]>     20120040884     <![CDATA[Method for Determining the Cbl-b Expression]]> http://www.patentstorm.us/applications/20120040864/description.html
  • Application Number:  20120040864
  • Publication Date:  2012-02-16
  • Inventors:  Loibner, Hans; Schuster, Manfred; Lametschwandtner, Gunther; Baier, Gottfried; Gruber, Thomas; Wolf, Dominik
    • The present invention relates to methods of determining intracellular Cbl-b protein in cells of a sample, comprising
      • introducing an antibody, which binds Cbl-b intracellularly, into a cell,
      • allowing contracting of the antibody and Cbl-b protein potentially present in the cell,
      • ]]> 20120040864 <![CDATA[ISOLATION OF FACTORS THAT ASSOCIATE DIRECTLY OR INDIRECTLY WITH CHROMATIN]]> http://www.patentstorm.us/applications/20120040857/description.html
      • Application Number:  20120040857
      • Publication Date:  2012-02-16
      • Inventors:  Kingston, Robert; Dejardin, Jerome; Simon, Matthew
      Methods for isolating non-coding nucleic acids that are associated with chromatin at a target genomic locus are provided. The methods comprise the steps of obtaining a sample that comprises a target genomic DNA sequence and one or more non-coding nucleic acids associated with that DNA sequence; contacting the sample with at least one oligonucleotide probe that comprises a sequence that is complimentary to and capable of hybridising with at least a portion of the target DNA sequence, wherein the ...
      ]]> 20120040857 <![CDATA[Glycan-Specific Analytical Tools]]> http://www.patentstorm.us/applications/20120040474/description.html
    • Application Number:  20120040474
    • Publication Date:  2012-02-16
    • Inventors:  Woods, Robert J.; Yang, Loretta
    Provided are lectenz molecules, which are mutated carbohydrate processing enzyme enzymes that are catalytically inactive and that have had their substrate affinity increased by at least 1.2 fold. Further provided are methods for making and methods of using such lectenz. Additional mutated proteins following the lectenz approach are further ...
    ]]>     20120040474     <![CDATA[GLYPICAN-3 (GPC3)-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES USEFUL FOR HLA-A2-POSITIVE PATIENTS AND PHARMACEUTICAL COMPRISING THE SAME]]> http://www.patentstorm.us/applications/20120040452/description.html
  • Application Number:  20120040452
  • Publication Date:  2012-02-16
  • Inventors:  NISHIMURA, Yasuharu; NAKATSURA, Tetsuya; KOMORI, Hiroyuki
    • It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B):
    • (A) a ...
      ]]> 20120040452 <![CDATA[MOLECULES ABLE TO MODULATE THE EXPRESSION OF AT LEAST A GENE INVOLVED IN DEGRADATIVE PATHWAYS AND USES THEREOF]]> http://www.patentstorm.us/applications/20120040451/description.html
    • Application Number:  20120040451
    • Publication Date:  2012-02-16
    • Inventors:  Ballabio, Andrea; Sardiello, Marco
    A molecule being able to modulate the expression of at least a gene involved in degradative pathways so to enhance the cellular degradative pathways and prevent or antagonize the accumulation of toxic compounds in a cell and acting on a CLEAR element. Preferred molecules are: the TFEB protein, synthetic or biotechnological functional derivative thereof; chimeric molecule comprising the TFEB protein, synthetic or biotechnological functional derivative thereof; modulator of the TFEB protein ...
    ]]>     20120040451     <![CDATA[Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites]]> http://www.patentstorm.us/applications/20120040431/description.html
  • Application Number:  20120040431
  • Publication Date:  2012-02-16
  • Inventors:  Govindan, Serengulam V.; Moon, Sung-Ju; Chang, Chien-Hsing; Goldenberg, David M.
    • The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells ...
    ]]>     20120040431     <![CDATA[Method For Producing Proteins]]> http://www.patentstorm.us/applications/20120040401/description.html
  • Application Number:  20120040401
  • Publication Date:  2012-02-16
  • Inventors:  Ellis, Mark; Newnham, Laura Ellen
    • The invention relates to a transcriptionally active recombinant linear polynucleotide encoding a multimeric protein comprising in the following order, a first promoter sequence, a first encoding polynucleotide sequence, a bidirectional regulatory sequence, a second encoding polynucleotide sequence and a second promoter sequence, wherein the first and second encoding polynucleotide sequences are in convergent transcriptional orientation, each encoding polynucleotide sequence encodes a component ...
    ]]>     20120040401     <![CDATA[Novel Permanent Human Cell Line]]> http://www.patentstorm.us/applications/20120040400/description.html
  • Application Number:  20120040400
  • Publication Date:  2012-02-16
  • Inventors:  Volpers, Christoph; Schiedner, Gudrun
    • The present invention relates to a permanent human cell line comprising a nucleic acid sequence for the adenoviral gene functions E1A and E1B and the nucleic acid sequence for the SV40 large T-antigen or the Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1). Further, the present invention relates to a method for transient expression of recombinant polypeptides and proteins in said permanent human cell ...
    ]]>     20120040400     <![CDATA[Photo-Crosslinked Nucleic Acid Hydrogels]]> http://www.patentstorm.us/applications/20120040397/description.html
  • Application Number:  20120040397
  • Publication Date:  2012-02-16
  • Inventors:  Luo, Dan; Roh, Young Hoon
    • Methods and compositions are provided for producing hydrogel nucleic acid structures using photo-crosslinking. Methods of using the photo-crosslinked hydrogels for cell-free protein production, and for encapsulating and delivering compounds, are also ...
    ]]>     20120040397     <![CDATA[MICROTUMOURS]]> http://www.patentstorm.us/applications/20120040394/description.html
  • Application Number:  20120040394
  • Publication Date:  2012-02-16
  • Inventors:  Raju, Paul; Cui, Zhanfeng
    • A method of producing an in vitro microtumour comprising: seeding a colorectal neoplastic cell into a three dimensional scaffold comprising polysaccharide co-polymer; providing said cell with a culture medium that supports the growth thereof; and incubating said cell in said scaffold for a time sufficient for microtumors to form, wherein said polysaccharide copolymer comprises glutaronate and ...
    ]]>     20120040394     <![CDATA[COAGULOGEN RAW MATERIAL, PROCESS FOR PRODUCING THE SAME, AND METHOD AND APPARATUS FOR MEASURING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN USING THE SAME]]> http://www.patentstorm.us/applications/20120040385/description.html
  • Application Number:  20120040385
  • Publication Date:  2012-02-16
  • Inventor:  Yabusaki, Katsumi
    • Disclosed is a technique for obtaining a coagulogen raw material which can irreversibly inactivate the activity of a coagulase while retaining the function of coagulogen in an LAL reagent, a LAL reagent contaminated by an organism-derived biologically active substance or the like, and which can be used in a reagent. An LAL reagent is heated at a predetermined temperature for a predetermined period of time to deactivate only the activity of an enzyme contained in the LAL reagent irreversibly, ...
    ]]>     20120040385     <![CDATA[Meprobromate Immunoassay]]> http://www.patentstorm.us/applications/20120040378/description.html
  • Application Number:  20120040378
  • Publication Date:  2012-02-16
  • Inventors:  Benchikh, Elouard; McConnell, Ivan; Fitzgerald, Peter; Lowry, Philip
    • Carisoprodol is a centrally-acting prescription drug of known abuse. Upon ingestion it is rapidly metabolised to meprobamate, also a prescription drug with abuse potential. Current immunoassays are specific for carisoprodol and therefore have a short window of detection and, furthermore, are ineffective at detecting meprobamate. The current invention, underpinned by an antibody specific for meprobamate, overcomes these ...
    ]]>     20120040378     <![CDATA[RECOGNITION OF CYP2E1 EPITOPES]]> http://www.patentstorm.us/applications/20120040377/description.html
  • Application Number:  20120040377
  • Publication Date:  2012-02-16
  • Inventor:  Njoku, Dolores Benedicta
    • A critical epitope of human cytochrome P4502E1 (CYP2E1) associated with the development of hepatic autoimmune disease, including methods and kits for diagnosis and prognosis using the critical epitope as a biomarker for hepatic autoimmune ...
    ]]>     20120040377     <![CDATA[LUNG CANCER DIAGNOSTIC POLYPEPTIDE, METHOD FOR DETECTING LUNG CANCER, AND METHOD FOR EVALUATING THERAPEUTIC EFFECT]]> http://www.patentstorm.us/applications/20120040376/description.html
  • Application Number:  20120040376
  • Publication Date:  2012-02-16
  • Inventors:  Toyama, Atsuhiko; Ueda, Koji; Nakagawa, Hidewaki; Sato, Taka-Aki
    • A novel biomarker for use in lung cancer diagnosis is ...
    ]]>     20120040376     <![CDATA[ANTI-MUC1 ANTIBODY]]> http://www.patentstorm.us/applications/20120040375/description.html
  • Application Number:  20120040375
  • Publication Date:  2012-02-16
  • Inventors:  Hinou, Hiroshi; Nishimura, Shin-Ichiro; Onoda, Junji; Numata, Yoshito; Naito, Shoichi; Ohyabu, Naoki
    • An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The ...
    ]]>     20120040375